After hearing arguments of the companies like Pfizer, Glenmark, Procter and Gamble and Cipla, the central government and some NGOs like All India Drug Action Network (AIDAN) over a span of over two months starting from March 14, Justice Rajiv Sahai Endlaw reserved judgement on the pleas questioning the Centre's decision.
The court had on March 14 stayed the Centre's March 10 ban on 344 FDC drugs and this interim order was passed in each and every case filed before it thereafter.
They had also argued that the ban order was passed without considering clinical data and termed as "absurd" government's claim that it took the decision to ban FDCs on the ground that safer alternatives were available.
The government had banned over 300 FDC drugs on the ground that they involve "risk" to humans and safer alternatives were available.